EGFR and colorectal carcinoma: Verteporfin (VP), As a YAP inhibitor, VP reverses paclitaxel resistance in HCT-8/T cells and significantly enhances the sensitivity of LOVO/TAX cells to paclitaxel when combined with the drug (120, 121), VP also suppresses migration and invasion of DLD-1 cells (122) and further inhibits CRC progression when combined with the EGFR inhibitor AG1478, reversing chemotherapy resistance (51).